NHS Branded Medicines Tranche Framework for London and South of England
NHS England
This tender has closed
The submission deadline for this contract has passed. There may be more active goods tenders from NHS England, and hundreds more across the UK public sector.
Key details
Procurement
- 33600000 Pharmaceutical products
What happened
NHS England awarded this contract to Sun Pharma UK Ltd | Biogen | Merck Sharpe & Dohme (UK) Limited | Celltrion Healthcare United Kingdom Limited | AstraZeneca | Janssen-Cilag Ltd | Organon Pharmaceuticals UK Ltd | Thornton and Ross Ltd | GlaxoSmithKline UK Limited | Takeda UK Ltd | Pfizer Ltd | Novartis Pharmaceuticals UK Ltd | Zentiva Pharma UK Ltd | Roche Products Ltd | Eli Lilly & Company Ltd | Aventis Pharma ltd t/a Sanofi | Accord-UK Ltd | Orifarm UK | Galapagos Biotech Ltd | Manx Healthcare Ltd | Chugai Pharma UK Ltd | Napp Pharmaceuticals Ltd | Dr.Reddy's Laboratories (UK) Limited | LEO Pharma | Gedeon Richter UK Ltd | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | Sobi (Swedish Orphan Biovitrum Ltd) | Teva UK Limited | UCB Pharma Ltd (primary) worth £380,950,720 on 22 Jul 2024. The contract runs until 31 Aug 2026.
Description
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024
Offer reference number: CM/PHR/22/5689
CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
Awarded suppliers (29)
- Sun Pharma UK Ltd
- Biogen
- Merck Sharpe & Dohme (UK) Limited
- Celltrion Healthcare United Kingdom Limited
- AstraZeneca
- Janssen-Cilag Ltd
- Organon Pharmaceuticals UK Ltd
- Thornton and Ross Ltd
- GlaxoSmithKline UK Limited
- Takeda UK Ltd
- Pfizer Ltd
- Novartis Pharmaceuticals UK Ltd
- Zentiva Pharma UK Ltd
- Roche Products Ltd
- Eli Lilly & Company Ltd
- Aventis Pharma ltd t/a Sanofi
- Accord-UK Ltd
- Orifarm UK
- Galapagos Biotech Ltd
- Manx Healthcare Ltd
- Chugai Pharma UK Ltd
- Napp Pharmaceuticals Ltd
- Dr.Reddy's Laboratories (UK) Limited
- LEO Pharma
- Gedeon Richter UK Ltd
- BIOSIMILAR COLLABORATIONS IRELAND LIMITED
- Sobi (Swedish Orphan Biovitrum Ltd)
- Teva UK Limited
- UCB Pharma Ltd (primary)
Contact
Identifiers
Explore related tenders
Other tenders from NHS England
View all →External ID: cf-ocds-b5fd17-093f7927-fa77-4248-beb7-0c8a9707d58c • Added 3 October 2026